ijms-logo

Journal Browser

Journal Browser

Recent Advances in the Pathogenesis, Treatment and Development of New Drugs against Helicobacter pylori and Campylobacter jejuni

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Microbiology".

Deadline for manuscript submissions: 20 December 2024 | Viewed by 2021

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Biochemistry and Molecular & Cellular Biology, University of Zaragoza, Zaragoza, Spain
2. Group of Translational Research in Digestive Diseases, Institute for Health Research Aragon (IIS Aragón), Zaragoza, Spain
Interests: Helicobacter; Campylobacter; new antimicrobial targets; bacterial transcriptional regulators; precision antimicrobials; antimicrobial resistance

E-Mail Website
Guest Editor
Department of Medical Microbiology, Wroclaw Medical University, 50-368 Wroclaw, Poland
Interests: Helicobacter pylori; biofilm; coccoid forms; morphology; outer membrane vesicles; antibiotic tolerance; antimicrobial/antibiofilm activity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Helicobacter pylori and Campylobacter jejuni are two clinically relevant gastrointestinal pathogens belonging to the phylum Campylobacterota (formerly Epsilonproteobacteria class). H. pylori is considered the most prevalent bacterial pathogen causing chronic infection in humans, affecting more than half of the global population. This microaerophilic, spiral-shaped and lophotrichous-flagellated bacterium has coevolved with humans colonizing the gastric epithelium. Untreated, long-term infection with this pathogen induces progressive and chronic inflammation of gastric mucosa which may lead to atrophic gastritis, peptic ulcer disease, gastric adenocarcinoma, and mucosa associated lymphoid tissue (MALT) lymphoma. H. pylori has been associated with 90% of non-cardia gastric cancer worldwide, and it is at present the only bacterial pathogen classified as a class I carcinogen.

C. jejuni constitutes the etiological agent of 80–90% of all cases of diagnosed campylobacteriosis worldwide, being recognized as the major cause of bacterial food-borne gastroenteritis. This microaerophilic amphitrichous-flagellated bacterium is part of the commensal microbiota of different avian species and other wild and domestic animals, including pets. Infection in humans is generally acquired through the fecal–oral route by the consumption of contaminated meat (mainly chicken), milk, fruits and vegetables, but also after the exposure to soils or water sources contaminated with animal feces. Campylobacteriosis usually produces mild and self-limited bloody diarrhea, accompanied by fever and stomach cramps. However, the infection could lead to severe complications like bacteriemia, meningitis, endocarditis, and Guillain-Barre syndrome, which may cause death in very young children, elderly and immunocompromised people.

The increasing development of antibiotic resistance, the quite spread of multidrug-resistant strains, and the alarming decrease in the efficacies of first-line antimicrobial therapies in last decades have determined that World Health Organization (WHO) considered H. pylori and C. jejuni as “priority pathogens” in the global efforts to R&D of novel antimicrobials. With this Special Issue, we would like to provide a collection of high-quality original research articles and reviews that significantly contribute to the progress of knowlegment in the fields of pathogenicity, treatment and finding of novel therapeutic targets and drugs against these two human bacterial pathogens.

Dr. Andrés González
Dr. Paweł Krzyżek
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Helicobacter pylori
  • Campylobacter jejuni
  • pathogenesis
  • antimicrobial therapies
  • antimicrobial resistance
  • new drug targets
  • novel antibiotics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

27 pages, 4259 KiB  
Article
Novel Drug-like HsrA Inhibitors Exhibit Potent Narrow-Spectrum Antimicrobial Activities against Helicobacter pylori
by Javier Casado, Irene Olivan-Muro, Sonia Algarate, Eduardo Chueca, Sandra Salillas, Adrián Velázquez-Campoy, Elena Piazuelo, María F. Fillat, Javier Sancho, Ángel Lanas and Andrés González
Int. J. Mol. Sci. 2024, 25(18), 10175; https://doi.org/10.3390/ijms251810175 - 22 Sep 2024
Viewed by 1174
Abstract
Helicobacter pylori infection constitutes a silent pandemic of global concern. In the last decades, the alarming increase in multidrug resistance evolved by this pathogen has led to a marked drop in the eradication rates of traditional therapies worldwide. By using a high-throughput screening [...] Read more.
Helicobacter pylori infection constitutes a silent pandemic of global concern. In the last decades, the alarming increase in multidrug resistance evolved by this pathogen has led to a marked drop in the eradication rates of traditional therapies worldwide. By using a high-throughput screening strategy, in combination with in vitro DNA binding assays and antibacterial activity testing, we identified a battery of novel drug-like HsrA inhibitors with MIC values ranging from 0.031 to 4 mg/L against several antibiotic-resistant strains of H. pylori, and minor effects against both Gram-negative and Gram-positive species of human microbiota. The most potent anti-H. pylori candidate demonstrated a high therapeutic index, an additive effect in combination with metronidazole and clarithromycin as well as a strong antimicrobial action against Campylobacter jejuni, another clinically relevant pathogen of phylum Campylobacterota. Transcriptomic analysis suggests that the in vivo inhibition of HsrA triggers lethal global disturbances in H. pylori physiology including the arrest of protein biosynthesis, malfunction of respiratory chain, detriment in ATP generation, and oxidative stress. The novel drug-like HsrA inhibitors described here constitute valuable candidates to a new family of narrow-spectrum antibiotics that allow overcoming the current resistome, protecting from dysbiosis, and increasing therapeutic options for novel personalized treatments against H. pylori. Full article
Show Figures

Graphical abstract

Back to TopTop